Skip to main content

Table 4 The Top 20 Cited Papers in novel coronavirus (COVID-19) research

From: Mapping the situation of research on coronavirus disease-19 (COVID-19): a preliminary bibliometric analysis during the early stage of the outbreak

Ranking Authors Title Year Source title Cited by
1st Huang et al. [7] “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China” 2020 The Lancet 2554
2nd Wang et al. [9] “Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China” 2020 Journal of the American Medical Association 1507
3rd Guan et al. [46] “Clinical characteristics of coronavirus disease 2019 in China” 2020 New England Journal of Medicine 1469
4th Zhu et al. [47] “A novel coronavirus from patients with pneumonia in China, 2019″ 2020 New England Journal of Medicine 1393
5th Chen et al. [48] “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study” 2020 The Lancet 1322
6th Li et al. [49] “Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia” 2020 New England Journal of Medicine 1061
7th Zhou et al. [3] “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study” 2020 The Lancet 980
8th Wu and McGoogan [50] “Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention” 2020 Journal of the American Medical Association 964
9th Zhou et al. [51] “A pneumonia outbreak associated with a new coronavirus of probable bat origin” 2020 Nature 931
10th Chan et al. [52] “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster” 2020 The Lancet 805
11th Lu et al. [53] “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding” 2020 The Lancet 724
12th Holshue et al. [54] “First case of 2019 novel coronavirus in the United States” 2020 New England Journal of Medicine 585
13th Yang et al. [55] “Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study” 2020 The Lancet Respiratory Medicine 521
14th Wang et al. [56] “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro” 2020 Cell Research 507
15th Xu et al. [57] “Pathological findings of COVID-19 associated with acute respiratory distress syndrome” 2020 The Lancet Respiratory Medicine 485
16th Van Doremalen et al. [58] “Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1″ 2020 New England Journal of Medicine 470
17th Hoffmann et al. [59] “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor” 2020 Cell 463
18th Rothe et al. [60] “Transmission of 2019-NCOV infection from an asymptomatic contact in Germany” 2020 New England Journal of Medicine 403
19th Mehta et al. [61] “COVID-19: consider cytokine storm syndromes and immunosuppression” 2020 The Lancet 389
20th Zou et al. [62] “SARS-CoV-2 viral load in upper respiratory specimens of infected patients” 2020 New England Journal of Medicine 387